louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03840720: The Patient's Journey - the Time to Final Diagnosis in Patients With SiNET
Official title: The Patient's Journey - Assessing the Time to Final Diagnosis in Patients With Neuroendocrine Tumors (NET) in Western Sweden
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neuroendocrine Tumors
Lead sponsor: Vastra Gotaland Region
Sponsor class: OTHER_GOV
Collaborators: name: Novartis
First posted: 2019-02-15
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients in Western Sweden, \> 18 years of age that has been diagnosed with a small intestinal neuroendocrine tumor during 2016-2018

Brief summary: "The patient's journey" is an interview based study assessing the patients' experience from the first symptoms to a final diagnosis focusing on patients with small intestinal neuroendocrine tumors.

Detailed description: The project focus on patients with small intestinal neuroendocrine tumors (SiNET's) with an incidence of 1-2/100 000 yearly. The primary tumor(s) are often small and symptoms usually arise when the disease has become metastatic with hormonal symptoms and/or symptoms due to local growth. As the tumors grow slowly and the symptoms in many cases are rather diffuse and develops gradually over a long time period there is often a long delay from onset to a final diagnosis both depending on "patient's delay" and "doctor's delay" The aim of the current project is to map and analyze the patient's journey from the first appearance of symptoms to the time point of a final diagnosis and to try to identify factors contributing to a delayed process.

The method is interview based and the interviews will be analyzed through the Design Thinking Methodology

Eligibility criteria: Inclusion Criteria:

* Patients living in Western Sweden
* \> 18 years of age
* Performance status 0-3
* Expected remaining survival of \> 6 months
* Diagnosed with a small intestinal neuroendocrine tumor during 2016-2018

Exclusion Criteria:

* Not able to read and/or understand Swedish language
* Dementia/memory loss
* Performance status \>3

Primary outcomes:
measure: Initial symptoms
timeFrame: October 2019
measure: Health care actions
timeFrame: October 2019
measure: Reasons for a delayed diagnosis
timeFrame: October 2019
Secondary outcomes:
measure: Patients' efforts
timeFrame: October 2019
Other outcomes:
Locations:
city: Gothenburg
country: Sweden
facility: Dept of Oncology
Study officials:
affiliation: Dept of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
name: Andreas Hallqvist, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04072120: Stroke Survival in Municipalities: Impact of Geographic Proximity to First- and Second-degree Relatives
Official title: Stroke Survival in Municipalities: Impact of Geographic Proximity to First- and Second-degree Relatives
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Stroke
Keywords: Stroke
Post-acute stroke
Geographical proximity
Family
Relatives
Survival analysis
Lead sponsor: University of Oslo
Sponsor class: OTHER
Collaborators: name: Extrastiftelsen
name: The National Association for Public Health, Norway
First posted: 2019-08-28
Enrollment: 7400000
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. All Norwegian residents in the period from 1960 to 2017 (n=7,4 mill), including all births and deaths(from the Cause of Death Registry) occurring in this population from 1960 onwards.
2. The Multigenerational Register in Statistics Norway covering family linkage on all individuals to their parents for all born after 1952 is included.
3. The Census from 1960, and from 1970 to 2011
4. Hospital data on hospital discharge from cardiovascular events among all Norwegians from 1992.

Brief summary: Our key objective will be to investigate if geographic proximity to first- and second-degree relatives has an influence on post-acute stroke survival and use of health and social services. We will also model and map spatial variation in stroke and cardiovascular disease (CVD) incidence and mortality and see if some of the variation is due to spatial clustering of familial risk. The study will use innovative approaches to large-scale registry and survey data and statistical analysis on the full Norwegian population. We will integrate multigenerational and geographical information. This will enable us to assess key determinants on stroke survival and use of health and social care at municipality level.


Eligibility criteria: Inclusion Criteria:

* Norwegian citizens aged 45 and above 1.1.1994 - 31.12. 2009 and had stroke events
* Those who attend a cardiovascular health survey who later developed stroke.
* All Norwegians born in the period 1 January 1940 to 31 December 1959 who survived to 1991
* Norwegian citizens aged 45 and above 1.1.2016 and had stroke events

Exclusion Criteria:

-

Primary outcomes:
measure: R1- Mortality
timeFrame: Mortality follow-up from 1.1.1994 to 31.12.2014
measure: R2- Mortality
timeFrame: Mortality follow-up from 1991-2014.
measure: R3- Stroke events
timeFrame: Stroke events registered in the Patient registry after 2016, (possibly until 2019)
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Department of Community Medicine and Global Health,University of Oslo
Study officials:
affiliation: Department of Community Medicine and Global Health, University of Oslo
name: Øyvind Næss, MD, MSc, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00512720: Clinical Outcomes of Three Different Percutaneous Revascularization Strategies for the Treatment of Lifestyle Limiting Claudication: A Retrospective Analysis
Official title: Clinical Outcomes of Three Different Percutaneous Revascularization Strategies for the Treatment of Lifestyle Limiting Claudication: A Retrospective Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Peripheral Artery Disease
Keywords: PAD
Peripheral Artery Disease
PVD
Peripheral Vascular Disease
Leg Blockage
Angioplasty
Stent
Claudication
Lead sponsor: Spectrum Health Hospitals
Sponsor class: OTHER
Collaborators: name: West Michigan Heart
First posted: 2007-08-08
Enrollment: 355
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: male and female over the age of 18 who have had Three Different Percutaneous Revascularization Strategies

Brief summary: To determine the effect of three different percutaneous revascularization strategies (Balloon Cryoplasty vs. Stent Placement vs. Atherectomy) in the treatment of lifestyle limiting lower extremity claudication

Detailed description: Endovascular revascularization of the superficial femoral artery (SFA) has become one of the most commonly performed endovascular procedures.The ability to offer the patient an alternative to surgical revascularization, limited by significant morbidity and mortality, with a same-day outpatient percutaneous procedure underlies the popularity of the endovascular approach. Although surgical bypass of the SFA remains the gold standard for revascularization, it is associated with significant morbidity and mortality.Comparative data between cryoplasty, angioplasty or stenting of the SFA will ultimately be required to provide more robust evidence of the efficacy of each mode of therapy.This registry is designed to determine the efficacy of three different percutaneous revascularization strategies (Cryoplasty vs. Stent Placement vs. Atherectomy) in the treatment of lifestyle limiting lower extremity claudication.

Eligibility criteria: Inclusion Criteria:

* Patients with Superficial Femoral Artery disease as assessed by angiography

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Grand Rapids
country: United States
facility: Spectrum Health
state: Michigan
Study officials:
affiliation: Spectrum Health Hospitals
name: Jihad Mustapha, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Spectrum Health Hospitals
name: Dennis Dunning, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00277420: Trial of a Culturally-Appropriate Weight Loss Intervention for Overweight Latino Children
Official title: A Randomized Controlled Trial of a Culturally-Appropriate Weight Loss Intervention for Overweight Latino Children
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Overweight
Lead sponsor: Medical College of Wisconsin
Sponsor class: OTHER
Collaborators: name: United Community Center
name: Milwaukee SCORES
name: Milwaukee Kickers Soccer Club
First posted: 2006-01-16
Enrollment: 0
Sex: ALL
Minimum age (years): 6
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This project aims to conduct a unique, community-based intervention consisting of a randomized trial of a culturally-appropriate weight loss intervention for overweight Latino children in Milwaukee. The intervention promotes lifestyle changes through a low weight loss regimen, one or more physical activities ranging from soccer to hip-hop dance, and dietary counseling including cooking classes for parents. In addition to weight reduction for overweight Latino children, the project has the potential to reduce missed school days and improve self-esteem and quality of life.


Eligibility criteria: Inclusion Criteria:

* Children must be of Latino descent
* At risk for becoming overweight or is overweight
* 6-17 years old.

Exclusion Criteria:

* Age \> 17 years old
* Not overweight or at risk for becoming overweight
* Non-Latino ethnicity/race.

Primary outcomes:
measure: change in body mass index (BMI) z-score
Secondary outcomes:
measure: height, weight, and BMI
measure: percent body fat
measure: physical activity
measure: sedentary activity
measure: dietary habits
measure: the child's quality of life
measure: self-esteem
measure: physical fitness
measure: selected health and use of health services measures (missed school days, parental missed work days, and number of healthcare provider visits for illness by child)
measure: the parents' BMI
measure: the child's satisfaction with opportunities to lose weight and increase physical activity in the past year
measure: the parents' satisfaction with opportunities for the child to lose weight and increase physical activity in the past year
measure: costs
Other outcomes:
Locations:
city: Milwaukee
country: United States
facility: Center for Advancement of Underserved Children (CAUC), Department of Pediatrics, Medical College of Wisconsin
state: Wisconsin
Study officials:
affiliation: Center for Advancement of Underserved Children (CAUC), Department of Pediatrics, Medical College of Wisconsin
name: Glenn Flores, MD
role: STUDY_DIRECTOR
affiliation: Assistant Professor of Pediatrics, Department of Pediatrics, Medical College of Wisconsin
name: Jane Brotanek, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Project Coordinator II, Center for Advancement of Underserved Children (CAUC), Department of Pediatrics, Medical College of Wisconsin
name: Julio C Maldonado, BA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05599620: Reducing Alcohol Use and Sexual Dysfunction in Survivors of Sexual Trauma
Official title: Reducing Alcohol Use and Sexual Dysfunction in Survivors of Sexual Trauma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Alcohol Use, Unspecified
Sexual Dysfunction
Sexual Assault
Lead sponsor: Lifespan
Sponsor class: OTHER
First posted: 2022-10-31
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 24
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The goal of this clinical trial is to develop and evaluate the preliminary efficacy of an intervention to address alcohol use, sexual distress, and sexual assault risk among college women with a history of sexual victimization. The main questions it aims to answer are: 1) what is the feasibility of the recruitment method, research design, interventionist training methods, and delivery of the intervention; 2) does the intervention, relatively to control, the 2- and 6-month follow-up produces reductions in the quantity/frequency of alcohol use and heavy drinking, sexual distress, and sex-related drinking motives, and sexual revictimization. Participants will engage in both individual and group based intervention for alcohol use, sexual distress, and sexual assault risk. Follow-up assessments are completed at 2- and 6-months following program completion. The intervention will be compared to a general health promotion control group.


Eligibility criteria: Inclusion Criteria:

1. be between the ages of 18 and 24;
2. speak and comprehend English;
3. report a history of attempted or completed penetrative acts of sexual victimization (i.e., oral, vaginal, anal) since age 14 via incapacitation or force;
4. report exceeding the national recommended limits for daily drinking (4 or more for women) on two or more occasions in the past month;
5. report past month sexual activity;
6. exceed the clinical cut point on the Female Sexual Functioning Index.

Exclusion Criteria:

1. suicide risk on the Beck Depression Inventory;
2. screen positive on the Alcohol Use Withdrawal Checklist.

Primary outcomes:
measure: Alcohol Use
timeFrame: Change from baseline alcohol use at 6 months.
measure: Sexual Distress
timeFrame: Change from overall levels of sexual dysfunction at 6 months.
measure: Sexual Victimization
timeFrame: Reductions in severity and frequency of victimization in comparison to control at 6 months.
Secondary outcomes:
measure: Sex-Related Drinking Motives
timeFrame: Change in sexual related drinking motives at 6 months.
Other outcomes:
Locations:
city: Providence
country: United States
facility: Rhode Island Hospital
state: Rhode Island
Study officials:
References:
Clinical trial NCT04368520: Clinical Trial to Optimise Levels of Vitamin D for Rhinovirus Protection
Official title: Clinical Trial to Optimise Levels of Vitamin D for Rhinovirus Protection (COLD)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Common Cold
Keywords: Rhinovirus
Lead sponsor: Queen Mary University of London
Sponsor class: OTHER
Collaborators: name: Imperial College London
First posted: 2020-04-29
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two treatment arms of vitamin D3: low dose (800IU) vs. high dose (3,200IU) given daily, for 3 months
Primary purpose: PREVENTION

Brief summary: A phase II randomised, placebo-controlled trial to identify the optimal regimen of vitamin D supplementation for rhinovirus protection, determined by host responses to a clinically induced rhinovirus challenge. The primary outcome is rhinovirus titre after inoculation with rhinovirus; secondary outcomes are self-reported respiratory symptom scores, concentrations of cytokines and chemokines sampled from the nasal mucosa, and the transcriptional responses of nasal epithelial cells.


Eligibility criteria: Inclusion Criteria:

1. Age 18-70 years
2. Gives written informed consent
3. Serum 25-hydroxyvitamin D concentration \<75 nmol/L
4. Agrees not to take supplement containing vitamin D during participation
5. Agrees not to commence smoking or vaping during participation

Exclusion criteria:

1. Current smoker or vaper
2. Taken vitamin D supplement or other supplement containing vitamin D, in previous 3 months
3. Sunny holiday abroadI, defined as any location 51 degrees North/South of the equator, for ≥1 week, in the previous 3 months
4. Dependent(s) \<6 months old
5. Positive serology for anti-RV16 antibodies
6. Living with someone with severe airways disease
7. Any of the following medical conditions:

   1. Diabetes mellitus
   2. Asthma
   3. Chronic Obstructive Pulmonary Disease
   4. Respiratory allergies
   5. Sarcoidosis
   6. Hyperparathyroidism
   7. Nephrolithiasis
   8. Active tuberculosis
   9. Liver failure
   10. Renal failure
   11. Lymphoma or other malignancy not in remission for ≥ 3 years

Primary outcomes:
measure: Rhinovirus titres
timeFrame: +3 to +5 days after inoculation
Secondary outcomes:
measure: Respiratory symptom score (Jackson Score)
timeFrame: +1 to +14 days after inoculation
measure: Cytokine and chemokine concentrations
timeFrame: Day 0 and +4 days after inoculation
measure: Change in level of vitamin D-regulated gene expression
timeFrame: Day 0 and +4 days after inoculation
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: St. Mary's Hospital
Study officials:
References:
Clinical trial NCT04473820: Comparison of Lidocaine-Prilocaine Combination and Vapocoolant for IV Cannulation Pain in the ED
Official title: Comparison of The Efficacy of Lidocaine-Prilocaine Combination and Vapocoolant Spray to Reduce Pain of IV Cannulation in The Emergency Department: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Pain
Lead sponsor: Tehran University of Medical Sciences
Sponsor class: OTHER
First posted: 2020-07-16
Enrollment: 77
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypothesis: Lidocaine-Prilocaine Combination is as effective as Vapocoolant in treating IV cannulation pain in the emergency department.

Detailed description: Lidocain-Prilocaine combination cream is two amide-type local anesthetics used for topical skin anesthesia. Vapocoolant spray is also another method for providing appropriate analgesia through crayoanesthetic mechanisms. Although there are some contraindications and adverse effects, these are widely used in the Emergency Department (ED) for IV cannulation pain.

Eligibility criteria: Inclusion Criteria:

* Low acute patients who are waiting for the admission to the ED and require IV cannulation

Exclusion Criteria:

* Altered mental status
* Uncooperative patients
* Unable to communicate
* Known history of hypersensitivity reaction to cold or amid analgesics
* Analgesic usage in previous 6 hours
* No consent
* Emergent condition
* Pregnancy and lactation

Primary outcomes:
measure: Cannulation pain: numerical rating score (NRS)
timeFrame: immediately after the procedure.
Secondary outcomes:
measure: Application pain: numerical rating score (NRS)
timeFrame: immediately after the procedure.
measure: Catheterization attempts
timeFrame: immediately after the procedure.
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: IKCH
Study officials:
References:
Clinical trial NCT06903520: Clinical Correlation Study Between Anomalous Pancreaticobiliary Ductal Junction and Malignant Tumors of the Biliary System and the Establishment of an AI-based Automated Recognition System
Official title: Clinical Correlation Study Between Anomalous Pancreaticobiliary Ductal Junction and Malignant Tumors of the Biliary System and the Establishment of an AI-based Automated Recognition System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreaticobiliary Maljunction
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2025-03-30
Enrollment: 2439
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with pancreaticobiliary maljunction

Brief summary: To explore the occurrence of pancreaticobiliary maljunction (PBM) in the Chinese population, the characteristics of various subtypes, and the relationship between PBM and malignant tumors of the biliary system. To explore the general clinical characteristics of patients with mild bile duct dilation but who have not been clinically diagnosed with choledochal cysts, as well as the relationship between these characteristics and malignant tumors of the biliary system. To develop and evaluate a deep learning method for machine learning of Magnetic resonance cholangiopancreatography (MRCP) images, enabling fully automated detection of pancreaticobiliary maljunction.


Eligibility criteria: Inclusion Criteria:

Cases that were hospitalized and underwent Magnetic resonance cholangiopancreatography (MRCP) examination at the First Medical Center of Chinese People's Liberation Army General Hospital.

Exclusion Criteria:

1. Patients aged less than 18 years old;
2. Those with unclear diagnosis;
3. Cases with missing or poor-quality imaging data.

Primary outcomes:
measure: The incidence rate of malignant tumors of the biliary system
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Chinese People's Liberation Army General Hospital
Study officials:
References:
Clinical trial NCT00209820: Nordic Walking and Chronic Low Back Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Low Back Pain
Keywords: low back pain
randomized clinical trial
Nordic walking
supervision
Advice to stay active
Lead sponsor: Human Locomotion Science
Sponsor class: OTHER
Collaborators: name: Nordic Institute of Chiropractic and Clinical Biomechanics
name: University of Southern Denmark
name: Hospitals of Funen
name: National Board of Health, Denmark
First posted: 2005-09-21
Enrollment: 150
Sex: ALL
Minimum age (years): 8
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a randimized clinical trial comparing the effect of supervised Nordic walking versus unsupervised Nordic walking versus advice to stay active


Eligibility criteria: Inclusion Criteria:

* Finished treatment at secondary sector specialist spinal unit
* Able to understand and read Danish

Exclusion Criteria:

* Co-morbidity preventing patient from completing Nordic walking program
* Pain \<3 on 11 point box scale
* Unable to perform Watt Max Cykel Test

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Ringe
country: Denmark
facility: Back Center Funen
state: Funen
Study officials:
affiliation: Back Center Funen, Ringe Denmark
name: Lars Morsø, PT
role: STUDY_DIRECTOR
affiliation: Nordic Institute of Chiropractic and Clinical Biomechanics
name: Jan Hartvigsen, DC, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Back Center Funen, Ringe, Denmark
name: Claus Manniche, MD, PhD
role: STUDY_CHAIR
References:
citation: Morso L, Hartvigsen J, Puggaard L, Manniche C. Nordic walking and chronic low back pain: design of a randomized clinical trial. BMC Musculoskelet Disord. 2006 Oct 2;7:77. doi: 10.1186/1471-2474-7-77.
citation: Hartvigsen J, Morso L, Bendix T, Manniche C. Supervised and non-supervised Nordic walking in the treatment of chronic low back pain: a single blind randomized clinical trial. BMC Musculoskelet Disord. 2010 Feb 10;11:30. doi: 10.1186/1471-2474-11-30.